Related Experiment Video
Updated: Mar 18, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
12.6K
A Study of the Newer Prognostic Markers in Diffuse Large B Cell Lymphomas
Kavita Sahai1, Vandana Gangadharan2, H P Singh3
1Senior Advisor (Pathology), Base Hospital, Delhi Cantt-10.
Medical Journal, Armed Forces India
|July 2, 2016
Summary
This study identifies distinct subtypes of Diffuse Large B Cell Lymphoma (DLBCL) in India. Germinal Centre B cell (GCB) DLBCL showed significantly better survival rates than non-GCB DLBCL.
Area of Science:
- Hematology
- Oncology
- Immunopathology
Background:
- Diffuse Large B Cell Lymphoma (DLBCL) is an aggressive cancer with distinct molecular subtypes.
- Gene expression profiling identifies Germinal Centre B cell (GCB) and Activated B cell (ABC) subtypes.
- These subtypes have different prognostic significance and therapeutic implications.
Purpose of the Study:
- To categorize DLBCL cases into GCB and non-GCB subtypes.
- To evaluate the prognostic significance of these subtypes in the Indian population.
Main Methods:
- Twenty DLBCL cases were analyzed.
- Immunohistochemistry using CD10, Bcl-6, MUM1, and CD138 antibodies was performed.
- Subtypes were defined based on specific marker expression patterns.
Main Results:
- Thirteen cases were classified as GCB DLBCL and seven as non-GCB DLBCL.
- GCB DLBCL comprised 75% of nodal and 62.5% of extranodal cases.
- Overall survival was 91% for GCB DLBCL versus 14% for non-GCB DLBCL, a statistically significant difference.
Conclusions:
- The study validates the existence of prognostically significant DLBCL subgroups in the Indian population.
- This classification aids in risk stratification and personalized treatment strategies for DLBCL patients in India.
